Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age at least 18 years and below 80 years at the time of signing informed consent~* Subjects diagnosed type 2 diabetes mellitus and treated with metformin monotherapy at a stable dose of at least 1500 mg daily or maximum tolerated dose above or equal to 1000 mg daily for at least 60 days prior to screening~* HbA1c 7.0-10.0% (both inclusive)~* Body mass index below or equal to 45.0 kg/m\^2~Exclusion Criteria:~* Treatment with glucose lowering agent(s) other than stated in the inclusion criteria in a period of 60 days prior to screening. An exception is short-term treatment (below or equal to 7 days in total) with insulin in connection with intercurrent illness~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Any chronic disorder or severe disease which at the discretion of the investigator might jeopardise subject's safety or compliance with the protocol~* Screening calcitonin value above or equal to 50 ng/l~* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2~* Diagnosis of malignant neoplasm in the previous 5 years (except basal cell skin cancer or squamous cell skin cancer)~* Any contraindications to liraglutide, sitagliptin or metformin according to local labelling

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide 1.8 mg + metformin (Type: EXPERIMENTAL): 2-week screening period, 26-week treatment duration, and a 1-week follow-up period
- Sitagliptin 100 mg + metformin (Type: ACTIVE_COMPARATOR): 2-week screening period, 26-week treatment duration, and a 1-week follow-up period

Based on this trial design, predict the completion outcome and termination type (if applicable).